

Drug Monograph

Drug/Drug **Lotemax[®] SM (loteprednol etabonate) gel / Ophthalmic**
 Class: **“Soft” Corticosteroid**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Lotemax[®] SM is now available a sterile preserved ophthalmic gel containing 3.8 mg of loteprednol etabonate per gram.

Manufacturer: Distributed by: Bausch & Lomb Incorporated, Bridgewater, NJ 08807.

Indications: Lotemax[®] SM is indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Costs: \$190.73 per 5 gram bottle of Lotemax[®] SM gel. Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List (PDL).

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit PDL

Type of PA Criteria: Increased Risk of ADE Preferred
 Appropriate Indications Under Solicitation

Prepared By: Carrie Gatzke PharmD
 Date: May 28, 2018